Efficacy and Safety of Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People’s Republic of China: a Systematic Review and Meta-Analysis
-
Published:2024-06
Issue:6
Volume:5
Page:100678
-
ISSN:2666-3643
-
Container-title:JTO Clinical and Research Reports
-
language:en
-
Short-container-title:JTO Clinical and Research Reports
Author:
Chen Qi-An,
Ma Kai,
Zhang Lin,
Lin Wei-Hao,
Wu Xian-Xian,
Gao Yi-BoORCID
Reference51 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Cancer incidence and mortality in China, 2016;Zheng;J N Atl Cancer Cent,2022
3. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008
4. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study;Garon;J Clin Oncol,2019
5. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis;Dafni;Lung Cancer,2019